FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Suicidal Ideation Effectiveness and Safety Outcomes from the Ketamine for Adult Depression Study (KADS). PMID 42105367 · Arch Suicide Res · 2026-May-09 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Intraoperative biodegradable stent placement to reduce complications after pancreatoduodenectomy - interim results from a randomised clinical trial. PMID 42104174 · Langenbecks Arch Surg · 2026-May-09 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Long-term effects of colonoscopy screening on colorectal cancer incidence and mortality: a multicountry, population-based randomised controlled trial. PMID 42102826 · Lancet · 2026-May-09 The study is a randomized, Phase III trial in oncology with original results, but it is excluded because it does not involve a drug-containing intervention (colonoscopy is a screening procedure) and does not have a primary or key secondary time-to-event efficacy endpoint (outcomes are cumulative incidence and mortality risk ratios, not time-to-event analyses like OS, PFS, DFS, EFS, RFS, or TTP, and no Kaplan-Meier or HR is reported). |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Understanding randomized controlled trial generalizability through an embedded molecular diagnostics trial. PMID 42026952 · JNCI Cancer Spectr · 2026-May-09 The study is a randomized controlled trial (RCT) embedded within a genomic diagnostics trial for prostate cancer, but it is not a drug-intervention trial. It compares treatment patterns (secondary treatment rates and time to treatment) between trial participants and real-world cohorts, but the intervention is a genomic classifier, not a drug. The time-to-event endpoint is time to secondary treatment, but this is not a standard efficacy endpoint (e.g., OS, PFS, DFS) for a drug-containing intervention. The phase is not established as Phase III/IIIb or Phase II/III. Therefore, it does not meet the eligibility criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Placebo Response in Phase II-III Symptom Intervention Studies: A Focus on Chemotherapy-Induced Peripheral Neuropathy and Associated Neuropathic Pain. PMID 42192875 · Cancers (Basel) · 2026-May-08 The record describes a meta-analysis and pooled analysis of placebo response rates in multiple trials, not the primary results of a single Phase III randomized trial with a time-to-event efficacy endpoint. The study focuses on symptom outcomes (neuropathy response rates) and does not report OS, PFS, DFS, EFS, RFS, TTP, or Kaplan-Meier/HR analyses. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The convenience of contrast-enhanced intraoperative ultrasonic cholangiography in liver resection: a study protocol for a randomized, prospective, off-label trial. PMID 42104300 · BMC Surg · 2026-May-08 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Efsubaglutide alfa added to metformin improves glycaemia with β-cell functional responses in type 2 diabetes: a randomised, double-blind, placebo-controlled, two-stage adaptive phase 2b/3 trial (SUPER 2). PMID 42103705 · Nat Commun · 2026-May-08 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Tocilizumab Biosimilars versus Reference Tocilizumab in Rheumatoid Arthritis: A Meta-Analysis of Pharmacokinetic Biosimilarity, Efficacy, Safety, and Immunogenicity. PMID 42102037 · Pharmacology · 2026-May-08 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| A Noddings' caring theory-based intervention to enhance coping with death competence in advanced lung cancer patients: a randomized controlled trial. PMID 42101688 · Support Care Cancer · 2026-May-08 Eligibility fails due to the absence of a drug intervention and a time-to-event efficacy endpoint. The study is a randomized trial in advanced lung cancer, but the intervention is non-pharmacological, and outcomes are psychological, not tumor-related time-to-event endpoints like OS or PFS. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial. PMID 42098105 · Nat Commun · 2026-May-08 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Smoldering Multiple Myeloma: Early Intervention or Structured Surveillance? A Comprehensive Review of Evidence for and Against Early Therapy. PMID 42192867 · Cancers (Basel) · 2026-May-07 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Existential distress in advanced cancer: study protocol of a pragmatic randomized controlled trial of a short-term psychodynamic therapy (ORPHYS) compared to usual psycho-oncological treatment (TAU). PMID 42098804 · Trials · 2026-May-07 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Comparing keystone and Limberg flaps for pilonidal sinus: Does flap choice influence patient satisfaction? PMID 42098544 · Tech Coloproctol · 2026-May-07 未发现恶性肿瘤人群证据。 |
B
|
仅广召回影子组 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Dose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions (DESTINATION 2): protocol for a randomised, phase II/R-IDEAL2b trial. PMID 42097645 · BMJ Open · 2026-May-07 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Low-frequency rTMS in combination with nicotine replacement therapy for smoking cessation: a phase II non-comparative Fleming-type randomized, double-blind, sham-controlled trial. PMID 42096636 · Nicotine Tob Res · 2026-May-07 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of Brivaracetam as an adjunctive therapy in patients with focal-onset seizures: a phase III, multi-center, randomized, double-blind, placebo-controlled trial. PMID 42092987 · Acta Epileptol · 2026-May-07 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Combined Oral Ivermectin and 5% Permethrin Cream to Treat Severe Scabies. PMID 42090793 · N Engl J Med · 2026-May-07 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults. PMID 42090792 · N Engl J Med · 2026-May-07 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Left Ventricular Unloading in High-Risk Percutaneous Coronary Intervention. PMID 41910380 · N Engl J Med · 2026-May-07 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| A randomized controlled trial of metastasis-directed therapy for oligometastases in breast cancer: OLIGAMI trial (JCOG2110). PMID 41615067 · Jpn J Clin Oncol · 2026-May-07 The record describes a randomized controlled trial protocol for a Phase III (implied by the question of superiority) study of metastasis-directed therapy plus systemic drug therapy versus systemic drug therapy alone for oligometastatic breast cancer, with overall survival as the primary endpoint. However, it is a protocol abstract without reported results, the phase is not explicitly stated as Phase III/IIIb or Phase II/III, and while systemic drug therapy is part of the intervention, it is not specified as a drug-containing intervention in a way that can be confirmed from the abstract alone (it could be non-drug therapy). Therefore, it does not meet the criteria for an original formal-result report of a randomized trial with a drug-containing intervention. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Long-term efficacy and safety results of betibeglogene autotemcel gene therapy for transfusion-dependent β-thalassemia. PMID 41525466 · Blood · 2026-May-07 The study reports on a gene therapy for transfusion-dependent β-thalassemia, a hematologic disorder but not a malignant neoplasm. The primary efficacy outcomes are transfusion independence and hemoglobin levels, which are not time-to-event endpoints like OS, PFS, or DFS. While the study includes a phase 3 component and reports long-term efficacy results, it fails the fundamental oncology criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): A systematic review and meta-analysis. PMID 42275677 · Am J Surg · 2026-May-06 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Safety and efficacy of switching to bictegravir-lenacapavir versus continuing bictegravir-emtricitabine-tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2): a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial. PMID 42105781 · Lancet HIV · 2026-May-06 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Event rates in major Phase 3 heart failure trials over the last 20 years. PMID 42275607 · ESC Heart Fail · 2026-May-05 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Survival outcomes in POD1UM-303/InterAACT-2: a phase 3 study of retifanlimab plus carboplatin-paclitaxel in first-line advanced squamous anal cancer. PMID 42097353 · Ann Oncol · 2026-May-05 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Clobetasol Propionate Ophthalmic Suspension to Treat Ocular Inflammation and Pain after Uncomplicated Cataract Surgery. PMID 42097332 · Ophthalmology · 2026-May-05 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Fragility Analysis of Cardiovascular Outcomes with Finerenone in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. PMID 42087276 · Eur J Heart Fail · 2026-May-05 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Improvement in Health-Related Quality of Life in Patients with Moderate to Severe Crohn's Disease Treated with Risankizumab vs Ustekinumab in the Phase 3B SEQUENCE Study. PMID 42085631 · Am J Gastroenterol · 2026-May-05 The study is a Phase 3b randomized trial of drug interventions (risankizumab vs ustekinumab) in humans and reports original primary results. However, it is not an oncology study (focus is Crohn's disease) and its endpoints are quality-of-life (IBDQ, SF-36) and symptom improvements, not the required time-to-event efficacy endpoints. |
S
B
|
严格 v3 独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Bimekizumab safety and efficacy in patients with psoriatic arthritis: 3-year results from two phase 3 studies. PMID 41838419 · Rheumatology (Oxford) · 2026-May-05 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Phase 2b trial of an oral relaxin family peptide receptor 1 agonist in patients with chronic heart failure: rationale and design. PMID 41711202 · ESC Heart Fail · 2026-May-05 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Current and emerging therapies in IDH-mutant glioma. PMID 42085879 · Neurotherapeutics · 2026-May-04 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| NH600001, an etomidate analogue, provides gastrointestinal endoscopy sedation/anesthesia and reduces adrenocortical depression: two randomized controlled trials. PMID 42082491 · Nat Commun · 2026-May-04 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcoma. PMID 42082272 · J Immunother Cancer · 2026-May-04 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Phase II trial of combination radiation, hormone, and immunotherapy in grade group 5 prostate cancer. PMID 42082271 · J Immunother Cancer · 2026-May-04 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Efficacy of Renin-Angiotensin System Inhibitors in Long-Term Oncologic Outcomes of Patients With Stage II/III Colon Cancer and Hypertension: A Target Trial Emulation. PMID 42081750 · JCO Oncol Pract · 2026-May-04 The study is a retrospective observational cohort, not a randomized controlled trial. It does not meet the required criteria for a Phase III/IIIb or Phase II/III randomized trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| From diabetes to tumor growth: unravelling the impact of glucose-lowering therapies. PMID 42081011 · Endocrine · 2026-May-04 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Intraoperative endoscopic pylorus dilatation during minimally invasive Ivor Lewis oesophagectomy to prevent delayed gastric conduit emptying (DGCE): protocol for the WIDE randomised controlled trial. PMID 42082244 · BMJ Open · 2026-May-03 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Hematoma Interleukin-1 Receptor Antagonist Concentrations Predict Long-Term Outcome in Acute Human Intracerebral Hemorrhage. PMID 42071280 · Ann Neurol · 2026-May-03 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Doublet versus triplet therapy in Indian patients with locally advanced & metastatic gall bladder cancer: a randomised trial. PMID 42069801 · Sci Rep · 2026-May-02 The record is an oncology randomized trial with drug interventions and primary time-to-event endpoints (PFS, OS). However, the explicit trial phase (III/IIIb or II/III) is not provided in the title, abstract, or metadata, and the deterministic review signals phase3 as false. Therefore, the 'phase3_or_definitive' criterion cannot be established, making the report ineligible. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trial. PMID 42030965 · Lancet · 2026-May-02 未发现恶性肿瘤人群证据。 |
H
L
B
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST). PMID 41880871 · Eur J Cancer · 2026-May-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Stereotactic body radiotherapy versus hepatic resection for recurrent small hepatocellular carcinoma: A post-hoc analysis with propensity score adjustment from two randomized trials. PMID 41833569 · Eur J Cancer · 2026-May-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Tumor burden in metastatic colorectal cancer quantified using deep learning models: Prognostic value and maintenance treatment benefit in the CAIRO3 trial. PMID 41819026 · Eur J Cancer · 2026-May-02 The record is from a randomized, drug-intervention, oncology trial with time-to-event endpoints, but the specific analysis presented is an exploratory biomarker subgroup analysis, not the primary or key secondary result of the trial. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Vunakizumab for Radiographic Axial Spondyloarthritis: A Randomized Clinical Trial. PMID 42101839 · JAMA Netw Open · 2026-May-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Tr14 gel compared to diclofenac gel after acute unilateral ankle sprain: an Individual Patient Data (IPD) meta-analysis of two multi-center trials. PMID 42067889 · BMC Musculoskelet Disord · 2026-May-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Biosimilar anti-vascular endothelial growth factor agents: Clinical outcomes, safety, and cost-effectiveness in India. PMID 42054089 · Indian J Ophthalmol · 2026-May-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant chemotherapy for soft-tissue sarcoma of the extremities: A post-hoc Sarculator-based risk analysis of the EORTC 62961-ESHO 95 randomized trial. PMID 42035475 · Cancer · 2026-May-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studies. PMID 41974026 · Hepatol Commun · 2026-May-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Robustness of highly purified eicosapentaenoic acid trials and their cardiovascular outcomes. PMID 41870913 · J Cardiovasc Med (Hagerstown) · 2026-May-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Nutritional supplements: current evidence for retinitis pigmentosa and Stargardt disease. PMID 41861379 · Curr Opin Ophthalmol · 2026-May-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |